CSCIF (Cosciens Biopharma) Current Accrued Expense: $0.21 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CSCIF Cosciens Biopharma Inc CSCIF
61 GF Score
Price $5.50
GF Value $7.02
Valuation Modestly Undervalued
! 4 Warning Signs
View Full Analysis

What is Cosciens Biopharma Current Accrued Expense?

Cosciens Biopharma CSCIF 61 Current Accrued Expense is $0.21 Mil as of Jun. 2026. GuruFocus rates CSCIF with a GF Score™ of 61/100 and a GF Value™ of $7.02 (Modestly Undervalued). The stock has 4 warning signs investors should review.

Cosciens Biopharma's Current Accrued Expense for the quarter that ended in Jun. 2026 was $0.21 Mil.

Cosciens Biopharma's quarterly Current Accrued Expense declined from Dec. 2025 ($0.68 Mil) to Mar. 2026 ($0.00 Mil) but then increased from Mar. 2026 ($0.00 Mil) to Jun. 2026 ($0.21 Mil).

Cosciens Biopharma's annual Current Accrued Expense increased from Dec. 2023 ($0.60 Mil) to Dec. 2024 ($1.69 Mil) but then declined from Dec. 2024 ($1.69 Mil) to Dec. 2025 ($0.68 Mil).

Cosciens Biopharma Current Accrued Expense Related Terms

Cosciens Biopharma Current Accrued Expense Historical Data

* Premium members only.

The historical data trend for Cosciens Biopharma's Current Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cosciens Biopharma Current Accrued Expense Chart

Cosciens Biopharma Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Current Accrued Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.54 1.28 0.60 1.69 0.68

Cosciens Biopharma Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Current Accrued Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.97 0.65 0.68 0.00 0.21
CSCIF
61GF Score
Cosciens Biopharma Inc CSCIF
Current Accrued Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cosciens Biopharma Current Accrued Expense Calculation

Current Accrued Expense is the expense incurred during the accounting period, but not required to be paid until a later date. It includes compensation, interest, pensions and all other miscellaneous accruals reported by the company.

What does a Current Accrued Expense of $0.21 Mil mean?
Cosciens Biopharma (CSCIF) has a Current Accrued Expense of $0.21 Mil as of Jun. 2026. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cosciens Biopharma and its competitors.
Is Cosciens Biopharma's Current Accrued Expense too high?
Cosciens Biopharma's current Current Accrued Expense is $0.21 Mil. Overall, Cosciens Biopharma has a GF Score™ of 61/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Cosciens Biopharma's Current Accrued Expense compare to VRTX and REGN?
Cosciens Biopharma's Current Accrued Expense of $0.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Accrued Expense for a Biotechnology company?
A good Current Accrued Expense depends on the Biotechnology industry context. However, Current Accrued Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Accrued Expense mean?
A high Current Accrued Expense can signal that a stock is expensive relative to its fundamentals. Current Accrued Expense records the total amount of accrued expenses. View historical data on Cosciens Biopharma and its competitors. Cosciens Biopharma's current Current Accrued Expense is $0.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cosciens Biopharma stock overvalued right now?
Based on GuruFocus' analysis, Cosciens Biopharma (CSCIF) is currently considered Modestly Undervalued. The stock's GF Value™ is $7.02, compared to a current price of $5.50 — trading 21.7% below its estimated fair value. The current Current Accrued Expense is $0.21 Mil. Cosciens Biopharma's overall GF Score™ is 61/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Accrued Expense calculated?
Current Accrued Expense is calculated from a company's financial statements. For Cosciens Biopharma (CSCIF), the current Current Accrued Expense is $0.21 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Cosciens Biopharma (CSCIF) Overvalued in 2026?

Based on GuruFocus' analysis, Cosciens Biopharma stock appears to be undervalued. The current stock price of $5.50 is trading 21.7% below its estimated GF Value™ of $7.02. GuruFocus considers Cosciens Biopharma to be Modestly Undervalued.

Key valuation signals for CSCIF:

  • Current Accrued Expense: $0.21 Mil
  • GF Value™: $7.02 vs. price of $5.50 (21.7% below fair value)
  • GF Score™: 61/100 with 4 warning signs

No single metric tells the full story. See the CSCIF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Cosciens Biopharma Business Description

Other Exchanges ET8:GermanyCSCI:Canada
Address C/o Borden Ladner Gervais Llp, Suite 3400, 22 Adelaide Street West, Toronto, ON, CAN, M5H 4E3
Cosciens Biopharma Inc is a biopharmaceutical company developing and commercializing pharmaceutical and diagnostic products and active ingredients for the healthcare and cosmetics industries. It operates through two segments: Active Ingredient and Biopharmaceutical. The Active Ingredient segment, which generates maximum revenue, focuses on plant-based ingredients derived from oats and other renewable resources, including oat beta glucan, oat oil, and avenanthramides. The Biopharmaceutical segment focuses on the development and commercialization of therapeutics and diagnostic tests, including its product Macrilen, and advancing a pre-clinical pipeline targeting unmet medical needs, particularly in rare or orphan indications. It operates in Canada, Germany, the United States, and Austria.
61GF Score

Get the complete analysis for CSCIF

Current Accrued Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$5.50
Price
$7.02
GF Value